

Migraine Treatment



Dr. Kerry Knievel and the team at the Jan & Tom Lewis Migraine Treatment Program utilize a variety of strategies to identify the right treatment for the right patient.

→ **APPROXIMATELY 39 MILLION** men, women and children in the United States – one billion people worldwide – know the debilitating pain of migraine. Migraine is the second-leading cause of disability in this country.

The Jan & Tom Lewis Migraine Treatment Program at Barrow Neurological Institute is dedicated to the comprehensive care of patients suffering from migraine pain. Barrow accepts the challenge of treating patients deemed “untreatable” and prides itself on pushing the boundaries of medicine. With this in mind, the migraine program’s vision is to become the leading destination for the treatment of migraine in the Phoenix metropolitan area, the state of Arizona, and across the Southwest.

Barrow’s migraine experts have the tools and expertise to accurately diagnose and treat migraines to minimize their effects on daily life. The solutions may include medications, injections, physical therapy, yoga, or a combination of therapies. In addition, the program conducts groundbreaking, innovative research to find more effective therapies to prevent and treat migraine pain.



85%

of chronic migraine sufferers are women



1.2 MILLION

visits to the emergency department every year are for acute migraine attacks



157 MILLION

workdays are lost each year in the US due to migraine

ABOUT BARROW
NEUROLOGICAL INSTITUTE



#1 IN ARIZONA
#11 IN THE UNITED STATES
for neurology and neurosurgery



CLINICAL IMPACT

92,515

BNI Clinic visits

3,135

number of neurosurgeries

1,578

number of spine surgeries

\$2.8 MILLION

amount of charity care



GLOBAL IMPACT

54

visiting scholars, research fellows and observers from Mexico, India, Egypt, Pakistan, UK, Russia, China, Chile, Spain, Brazil, Japan, France, Italy, Kingdom of Saudi Arabia, Indonesia, Turkey, Germany, Poland, Colombia, Philippines, Israel, Argentina and Thailand.

PROGRAM ACCOMPLISHMENTS

Barrow is home to the world’s leading specialists in migraine and headache. We have assembled a powerhouse team to provide comprehensive, compassionate care. Furthering their expertise to better serve patients, Kerry Knievel, DO, Courtney Schusse, MD, and Glynnis Zieman, MD, **earned board certification in headache** from the United Council for Neurologic Subspecialties in spring 2019. Physician assistant Karissa Secora, MPAS, also **passed the National Headache Exam** in April 2019, which demonstrates and verifies expertise in preventing migraine, treating migraine pain, and managing symptoms. **Ms. Secora also was named PA of the Year by the Arizona State Association of Physician Assistants.**

She was selected for delivering exceptional clinical care and for being an integral part of the healthcare team at the Jan & Tom Lewis Migraine Treatment Program. Jennifer Robblee, MD, joined Barrow in November 2019 increasing our capacity to bring relief to migraine sufferers.



Jennifer Robblee, MD

In addition, education and outreach programs allow our experts to share their knowledge of migraine prevention and symptom management with other headache sufferers that may not be Barrow patients. We are now offering community yoga classes once a month. Yoga is proven to reduce stress, potentially preventing migraines, and it can alleviate migraine pain once it begins.

“Headache 101” teaches primary care providers how to provide pain relief for patients without sending them to a specialist, urgent care, or emergency department. Twenty-six physicians attended this intensive class, and an advanced course is being planned for 2020.

RESEARCH ADVANCES

Five clinical trials supported by the Jan & Tom Lewis Migraine Treatment Program are at various stages of approval with the Institutional Review Board. The team is also building a patient database for pressure disorder headaches that will enable better outcomes analysis.

Dr. Knievel is also leading a study on the diagnosis of primary headache disorders using ICHD (International Classification of Headache Disorders) 3 as the Gold Standard. Determining the most effective method between an online questionnaire and semi-structured interview could make the diagnostic process more efficient, maximizing the time patients and physicians spend together.



RESEARCH

320

active research studies

839

patients enrolled in
clinical trials

\$9 MILLION

in federal research
grant support

↑ Meet the Jan & Tom Lewis Migraine Treatment Program team (left to right): physician's assistant Karissa Secora, Dr. Courtney Schusse, Dr. Jennifer Robblee, Jan Lewis, Dr. Kerry Knievel, Dr. Glynnis Ziemann and program coordinator Soledad Barragan-Godinez

Two new medications may soon be available to patients seeking migraine relief. Ubrogepant, a rescue medication tested with patients in a Barrow clinical trial, is expected to be approved by the U.S. Food and Drug Administration. In December 2019, Rimegepant, a drug belonging to a new generation of acute migraine headache treatments, is also awaiting FDA approval. This medication will give patients another option for treating migraine, especially those with cardiovascular disease.

ON THE HORIZON

The migraine program's first fellow in headache, Shane Root, MD, will begin his training July 2020. This demonstrates Barrow and Dr. Knievel's commitment to training the next generation of migraine specialists to build on the program's accomplishments.

There are also plans to hire another physician's assistant to work with Dr. Robblee and meet the demands of the anticipated increase in patient volume.

Following the success of the Headache 101 education event, Dr. Knievel and the program team will host a more advanced headache class for community physicians. At Headache 201, attendees will learn how to administer nerve block injections and review some case studies to apply what they learned in Headache 101. This will take place in early 2020 in order to include Dr. Robblee.



DONOR IMPACT

\$3.98 MILLION

for basic and
translational research

\$3.65 MILLION

for strategic initiatives
including Barrow
Aneurysm & AVM Research
Center, Barrow Artificial
Intelligence Center,
neuroimaging and stroke

\$1.26 MILLION

for education and
fellowship programs

\$2.52 MILLION

for community
outreach programs

THANK YOU FOR YOUR SUPPORT

I cannot thank you enough for your generous support of the Jan & Tom Lewis Migraine Treatment Program. We are improving quality of life for our patients by teaching them how to prevent migraines or offering a variety of solutions for their pain. We would not be able to expand our program, discover new treatments, or educate the community without you.

With Gratitude,
Kerry Knievel, DO



↑ *Dr. Kerry Knievel and Karissa Secora, MPAC, celebrated Ms. Secora being named Physician's Assistant of the Year for Arizona.*

Barrow Neurological Foundation raises awareness and funding for patient care, medical education, community outreach and research offered at Barrow Neurological Institute. Barrow is an internationally-recognized leader in neurology, neurosurgery and neuroscience research, treating patients with a wide range of conditions, including brain and spinal tumors, concussion and brain and spinal traumas, neuromuscular diseases, stroke, cleft and craniofacial disorders, and cerebrovascular disorders. It is home to several centers of excellence, including the Ivy Brain Tumor Center, Muhammad Ali Parkinson Center and Gregory W. Fulton ALS and Neuromuscular Disease Center. www.SupportBarrow.org



Barrow Neurological Foundation
124 W. Thomas Rd., Ste. 250
Phoenix, AZ 85013
www.SupportBarrow.org

Angela Braun
Manager, Philanthropy
602.406.1035
Angela.Braun@DignityHealth.org